<DOC>
	<DOCNO>NCT01844180</DOCNO>
	<brief_summary>The objective study explore efficacy , safety tolerability ONO-2952 female subject Diarrhea-Predominant Irritable Bowel Syndrome ( IBS-D ) .</brief_summary>
	<brief_title>A Phase 2 , Multi-center Study Evaluate Efficacy Safety ONO-2952 Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome ( IBS-D )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>1 . Female 1865 year age ( inclusive ) 2 . Diagnosed IBS base follow criterion ( Rome III criterion ) : Symptom onset least 6 month prior diagnosis , Recurrent abdominal pain discomfort least 3 day per month past 3 month , Abdominal discomfort pain associate two follow least 25 % time : 1 . Improvement defecation 2 . Onset associate change frequency stool/defecation 3 . Onset associate change form ( appearance ) stool 3 . Diagnosed IBSD , define loose/watery stool ≥ 25 % hard/lumpy stool ≤ 25 % defecation Any structural abnormality gastrointestinal ( GI ) tract ( esophagitis gastritis ) History Crohn 's disease , ulcerative colitis , diabetes mellitus , lactose malabsorption , malabsorption syndrome , celiac sprue , upper GI symptom may impact assessment IBS symptom</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>IBS</keyword>
	<keyword>ONO-2952</keyword>
</DOC>